Abstract
Background

Magnitude of the diabetes epidemic in five selected countries
Diabetes mellitus is a significant health problem in many countries, including Australia, Canada, New Zealand, the United Kingdom (UK), and the United States (US). Table  1 shows the number of people affected by diabetes, deaths due to diabetes, and estimated economic costs in each of these five countries [1] [2] [3] [4] [5] [6] [7] . Absolute numbers of people with diabetes (diagnosed and undiagnosed) varied greatly from country to country. However, estimated crude prevalence rates were consistently around 4%-6%, and estimated crude case fatality ratios were between 2.5/ 1000 and 3.8/1000 per year (these may not reflect the quality of diabetes control across the nations as data collection systems were different).
It is predicted that the number of people worldwide with diabetes will double in the next generation [8] . As well as the suffering of individuals and their families, diabetes poses a huge economic burden to nations' health care systems, mostly due to expenditures relating to long term diabetes complications and hospitalisations. In the UK, it is estimated that the National Health Services expenditure on diabetes will account for ten percent of its total annual budget by 2011, double the level in 2004 (see Table 1 ).
Due to such huge human and economic costs, nations have intensified their efforts to combat diabetes. In Australia, the National Diabetes Strategy was implemented in 1999, following the designation of diabetes as a National Health Priority Area in 1996 [9] . The Canadian Diabetes Strategy was initiated in 1999 with substantial investments to establish a national partnership for effective prevention and control of diabetes [10] . Diabetes was identified as one of the 13 Priority Population Health Objectives in New Zealand in 2000, in an effort to reduce the impact of diabetes and population health inequalities [11] . In the US, the National Diabetes Education Program was launched in 1997 to improve prevention and management of diabetes [12] . In the UK, a National Service Framework for Diabetes was developed in 2003 with explicit care standards and delivery strategies [13] .
Diabetes epidemic among indigenous populations
Diabetes prevalence rates are much higher in indigenous populations of high income ex-colonial countries than in people of European origin. On average, American Indians and Alaskan Natives are 2.3 times as likely to have diabetes as non-Hispanic whites of similar age in the US [6] . In Canada, prevalence of diabetes among First Nations peoples is at least three times the national average [3] , and First Nations peoples with diabetes are 3-4 times more likely to suffer from heart disease and stroke. Maori and Pacific Island people in New Zealand have nearly three times higher prevalence of diabetes, and their mortality rates from diabetes in the 40-65 age group are nearly ten times higher than for Europeans [4] . While Aboriginal and Torres Strait Islander people in Australia experience three to four times higher prevalence of diabetes than in the general population [14] , their death rate associated with diabetes for the 35-54 years group is 27-35 times that of non-Indigenous Australians [15] .
Despite their diverse geographical locations, cultures and traditions, the epidemic of diabetes among indigenous peoples is largely driven by rapid social and environmental changes which aggravate preventable risk factors such as unhealthy diet, decreased physical activity and tobacco use [16] . The root causes of these lifestyle-related risk factors are the long history of dispossession, exclusion, discrimination and associated social and economic disadvantage (including poor income, education, employment and living conditions) among indigenous populations [17] .
Health systems performance for diabetes care
There is a renewed interest in developing and using quality indicators to measure and benchmark the performance of health care systems with regard to diabetes care. For example, National Health Priority Area diabetes indicators have been employed to report national progress on prevention and control of diabetes in Australia. Available data relating to such indicators were published in 1998, 2002 and 2008 [1, 18, 19] . The US annual National Healthcare Quality Report uses a set of 12 indicators to assess national performance in diabetes management [20] . Likewise, the US National Committee for Quality [7] . ‡ Based on diabetes as primary cause of death.
Assurance uses the Comprehensive Diabetes Care measure to assess the quality of diabetes services provided by managed care plans (commercial insurance, Medicare and Medicaid) [21] . Due to the diversity of the indictors across countries, it has been difficult to conduct an international comparison of diabetes care. Efforts in the development, specification, and field-testing of measures for diabetes care have been carried out in the form of international collaborations. The European Union Diabetes Indicators Project was conducted during 2000-2002 and a set of core and secondary indicators was proposed to monitor diabetes and its complications in European Union/European Free Trade Area countries [22] . An Organisation for Economic Co-operation and Development (OECD) health technical paper delineates recommended indicators for the quality of diabetes care at the health system level in OECD countries [23] . These indicators were selected using criteria assessing impact on health, policy importance, susceptibility to being influenced by the health care system, and feasibility of data collection. As Australia, Canada, New Zealand, the US, and the UK are all participating in the indicator development and will be the future users of such measures, it is useful to assess the availability of data derived from current systems to provide information for the indicators.
Objectives of this review
(1) To assess the availability and quality of data which can be used for constructing OECD diabetes indicators in five selected countries (Australia, Canada, New Zealand, the US, and the UK); (2) To compare the quality of diabetes management at the national level among these five countries using OECD indicators; and (3) To compare the quality of diabetes management among indigenous populations in Australia, Canada, New Zealand, and the US using these indicators.
Reasons for selecting these five countries in this review include: 1) they are all OECD countries with advanced economies; 2) indigenous health is an important issue in Australia, Canada, New Zealand and the US; and 3) while the UK is not related to the indigenous health issue, it has a health care system similar to those in Australia, Canada and New Zealand.
Methods
Search strategy for identification of data
A. Internet-based reports. As national level delivery of services and quality of care data are usually published in monographs or reports by health departments of national governments, websites of the five countries' health departments were first searched to identify publications related to diabetes care. Then, the websites of the leading national organisations relating to diabetes care in each country were also searched to obtain relevant reports. A list of internet sources for data searching is shown in Table 2 . The following terms were used for the search: diabetes and (family practice, general practice, primary care, outpatients, quality, audit, guideline adherence, quality indicators, performance) (terms in the brackets connected by or). The B. The reference list of each retrieved report was also scanned to identify relevant information sources.
Types of outcome measures
The OECD diabetes indicators were used to assess the quality of diabetes management [23] . These nine indicators cover clinical processes of diabetes care as well as proximal and distal outcomes (Table 3) . Notably, for proximal outcomes, no specific cut-points for HbA1c and LDL cholesterol have been recommended by the indicator developers, reflecting a lack of international consensus on the threshold levels of these outcome indicators. The use of the six process and proximal outcome indicators was based on robust evidence and international consensus [23] . The use of the distal outcome indicators have not been universally accepted due to operational concerns. However, these distal outcomes represent long term outcomes of diabetes care, providing insight into the long term outcomes of overall health care systems.
We initially attempted to retrieve relevant information from selected countries to construct all of these nine indicators. However, we found that data for the three distal outcome indicators were rarely available at the national level, mainly due to difficulties in obtaining relevant information on denominators (all patients with a diagnosis of diabetes) for these indicators. Therefore, this review will only report results regarding the six process and proximal outcome indicators.
Inclusion criteria
Types of data sources
Two types of data sources were included: routine data collection systems in health care; and cross-sectional studies (surveys). Cross-sectional studies or surveys are generally considered to be suitable designs for evaluating quality of health care [24] .
Types of populations
'Study' populations were required to meet the following three criteria:
1. With diagnosis of type 1 or type 2 diabetes; 2. Aged 16 years or more;
3. Drawn at the national level (e.g. from multiple provinces/states/regions). Data that focused on gestational diabetes were excluded.
Outcome measures
Data included were related to one or more of the six OECD process and proximal outcome indicators as specified in Table 3 .
Criteria for assessing data quality
We adapted a quality assessment tool for observational studies developed by Wong et al [25] . The adapted tool measured data quality in terms of sample representativeness, national coverage of data, measurement objectiveness and response rate (see Additional file 1). An overall quality assessment score is calculated to rate the data 
Review process and data abstraction
Initially, all reports/papers identified by the internet search were screened by the reviewer (DS) against the inclusion criteria, to identify potential reports/papers which merited full-text reviews. A second reviewer (ZW) repeated this process independently six months later for selection of reports/papers into the review. The full reports/papers that were identified as possibly meeting the inclusion criteria by either reviewer were retrieved for further assessment. At the full-text level, a standardised abstraction form was used independently by each reviewer to extract information on data sources, targeted populations, outcomes, and data quality. Any discrepancies of results between the reviewers were resolved through discussion and consensus.
When the same data sources provided multiple year reports, all relevant reports were reviewed. However, only the data from the most recent report (or from years 2005-2007 which most countries had data available) were included in this review.
In this paper, unless otherwise specified, the term "patients" refers to people diagnosed as having diabetes.
Results
One hundred and five reports/papers were initially identified by the internet search of 29 websites as specified in Table 2 ) (Figure 1 ). Of those reports/papers, 36 met our explicit inclusion criteria and their full-texts were retrieved for data abstraction. During the full-text review, 22 reports/papers failed to meet inclusion criteria, and the remaining 14 were included for the current review [1, 20, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Summary of identified data sources
The 14 reports related to 13 data sources which provided information relevant to the 6 OECD diabetes indicators (Table 4) . These data sources can be broadly categorised into three types: 1) medical record data -for example, the General Practice Divisions Information Online System in Australia, the Health Plan Employer Data and Information Set in the US, and the National Diabetes Audit in the UK; 2) administrative health insurance data, such as the Health Insurance Commission General Practice Statistics in Australia; and 3) population-based survey data -for example, the Canadian Community Health Survey.
Appraisal of data quality
As detailed in Table 5 , of the 13 data sources, two (13%) were assessed as of poor quality, three (23%) as of satisfactory quality, and eight (62%) as of good quality. The poor quality of the two Australian data sources was driven by lack of representativeness in sampling and relatively low national coverage of the data.
Processes of diabetes care
Availability of data Annual HbA1c testing, lipid testing, kidney function examination, and eye examination rates are shown in Tables 6 and 7 . Four countries (Australia, New Zealand, the US and the UK) had national data available for all of these four process measures, but Canadian data were available for only two process measures. Data sources varied between countries: Australian data were mainly derived from diabetes registers in general practice and specialist clinics; Canadian data were based on the Canadian Community Health Survey; the US data were collected through the Health Plan Employer Data and Information Set (HEDIS) using medical record audits; the UK data were from the National Diabetes Audit; and New Zealand data were from the National Get Checked Programme. Except for Canada, the main data for the other four countries are derived from health service records.
Comparison between countries
For across nation comparison, data need to be collected using similar methods and during similar time periods. Based on medical record data, the US and UK performed relatively well across the four process indicators when compared with Australia and New Zealand (Tables 6 and  7) . For example, annual HbA1c testing and lipid testing were delivered to 70-80% of patients in the US and UK; the corresponding figures for Australia and New Zealand were 50-60%.
Based on data from similar population level surveys in Canada and US, the former had higher annual HbA1c testing rate but relatively lower eye examination rate when compared with the latter.
Sub-group comparison within countries
In Australia, annual checks for the four care processes were consistently higher for patients receiving specialist services than those cared for solely in general practice (see Tables 6 and 7 ). Poor identification of Indigenous status of patients in medical records limited the potential to report corresponding data for Indigenous people.
Of diabetes patients registered in New Zealand, Pacific Islanders had the highest annual HbA1c, lipid and kidney function testing rates, followed by those of European origin. Delivery of the key processes of care to Maori people was relatively low.
In the US, diabetes patients on Medicaid tended to have lower annual checking rates for the four processes compared to those on Medicare or commercial insurance. Annual lipid testing and renal function examination rates were substantially lower among American Indians and Alaska Natives than general populations. Although the Canadian Community Health Survey collects information on Aboriginal status, the data on diabetes care among Aboriginal populations had not been reported at the time this review was completed.
Proximal outcomes
Availability of data related to HbA1c and lipid control
Four countries had data available to construct indicators for HbA1c and lipid control at the national level (see Tables 8 and 9 ). Australia and New Zealand data were based on diabetes registers, the US used clinical audit data from the HEDIS, and the UK data were obtained through the National Diabetes Audit. Additionally, HbA1c control data could be drawn from the periodical National Health and Nutrition Examination Survey in the US, and a national population-based survey (the AusDiab) in Australia.
Comparison between countries
A number of different laboratory methods are used to measure the HbA1c level, so the normal ranges for The HEDIS is a standardised tool used by the National Committee for Quality Assurance (NCQA) to collect performance data for managed care organisations. HEDIS data cover people enrolled in managed-care plans (commercial insurance The UK has established the National Clinical Audit Support Programme to assess current diabetes care at primary and secondary care sectors, and to review progress towards achieving the standards set out in the National Service Framework. HbA1c may vary between laboratories. Moreover, varying cut-points used in different countries' reports make international comparison difficult. For example, while HbA1c < 7.0% was reported for Australia and the US data, HbA1c < 8.0% was reported for New Zealand data, and cut-points of < 6.5%, 6.5%-7.5% and > 7.5% were used in the UK (Table 8) . Most of the diabetes clinical guidelines [38] [39] [40] set HbA1c less than 7.0% as optimal glycaemic control. Based on clinical data and allowing for adjustment of differences in HbA1c cut-points used, glycaemic control for patients in Australia and New Zealand appeared to be relatively better than patients in the US and UK (Table 8) .
Difficulties in comparing blood lipid control were caused by the diversity of lipid parameters (total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglycerides) and the varying cut-points employed (Table 9 ). According to the clinical guidelines from the US, New Zealand and Australia [38] [39] [40] [41] , recommended optimal lipid control for diabetes patients are as follows: total cholesterol < 4.0 mmol/L, LDL-cholesterol < 2.6 mmol/L (or 2.5), HDL-cholesterol > 1.0 mmol/L (or 1.1), and triglycerides < 1.7 mmol/L. Using total cholesterol control among patients as an example, the UK performed relatively better, followed by Australia and the US (Table 9) .
Sub-group comparison within countries
In Australia, patients in general practice were more likely to have optimal HbA1c control than those visiting specialist clinics (57% versus 38%). However, this preliminary comparison may not reflect true differences in the quality of care in these two different settings, as patients referred to specialist clinics tend to be those with uncontrolled diabetes or more complications. Regarding blood lipid control, patients visiting specialist diabetes clinics tended to have better total cholesterol control compared those cared for by GPs.
The proportion of New Zealand European patients with HbA1c less than 8.0% was higher than that among Maori or Pacific Islander counterparts (78% versus 56-60%).
The US data revealed that patients on Medicaid were more likely than those on Medicare or commercial insurance to have poor blood glycaemic control and an elevated LDL-cholesterol level. Control of HbA1c among American Indian and Alaska Native patients (31% with HbA1c < 7.0%) was poorer than that among general patients (range 30-46%) in the US (Table 8) .
Discussion
This internet-based review reveals that the five selected countries have various data collection systems which, to some extent, can be used to construct the OECD diabetes indicators for cross country comparison. Routine data collection mechanisms also allow countries to monitor long-term trends of diabetes care. While New Zealand and the US have relatively well developed data collection systems to assess diabetes care among indigenous populations at the national level, Australia and Canada lag behind substantially in this area and have no national level diabetes care data available for indigenous populations. Countries can learn from each other to strengthen data collection systems and to improve population-based diabetes care.
Existing data sources for constructing OECD indicators: strengths and weaknesses
Diabetes registries
Australia and New Zealand have national data derived from general practice diabetes registers to monitor utili- 
Administrative records: insurance billing data and electronic laboratory data
Administrative insurance data have been used in Australia and are planned to be used in Canada for surveillance of diabetes services [42] . The use of insurance data has a number of advantages, including: 1) coverage of nearly the entire population, due to publicly funded health insurance arrangements in these two countries; 2) these data are not subject to recall bias; and 3) computerised databases already exist. The use of Medicare occasions of service data (1993) (1994) (1995) (1996) (1997) in New South Wales (Australia) was found to be a reliable, timely and cost-efficient way to monitor health service utilisation for people with diabetes [43] . All of the four diabetes process indicators could be constructed using Medicare data at the national level for Australia [1] . To date, the use of Australian Medicare data to monitor diabetes care is on an ad hoc basis. If specific efforts are made to routinely analyse and report Medicare data at the national level, information provided for diabetes indicators will be valuable for policy makers, health providers, researchers and the public to combat and control diabetes. In the US, Medicare claims data are used by the Centres for Medicare and Medicaid Services to monitor quality of diabetes care for Medicare beneficiaries [44] . The Canadian National Diabetes Surveillance System [42] is a national standardised database linking three types of person-specific administrative data (Physician Claims File, Hospital File and Health Insurance Registry). The first report from the Canadian National Diabetes Surveillance System contained prevalence and mortality data. The 2008 report provides information on health services utilisation in terms of the number of visits to family physicians and specialists by patients [45] . Further development of the system has the potential to report national diabetes care data related to the four process indicators used in this review. Importantly, at the Canadian province level, there has been reported use of clinical and administrative data to evaluate diabetes care in terms of process indicators (e.g. in British Columbia) [46] .
One of the disadvantages in using administrative insurance data is that these data include only information on those who use health services; for people with diabetes, only those with a diagnosis from a health professional are included. Also, administrative data lack detailed information on characteristics of patients such as ethnicity, which prevents related sub-group analysis. Another drawback is that insurance data do not record the test results, for example, HbA1c and total cholesterol levels. Electronic laboratory data are becoming more common in many OECD countries. Therefore, it is possible to construct measures for HbA1c and lipid control from such data sources. The challenge is how to link these data with other data such as insurance billing records using a unique identifier for individual patients.
Auditing medical records
As illustrated in this review, data collection systems such as National Clinical Audit in the UK and the HEDIS in the US, which obtain data through auditing of medical records, provide all the information needed for the six OECD diabetes process and proximal outcome indicators. The quality of data from the clinical audits is generally good. With a more widespread use of electronic medical records, clinical auditing will be less labourintensive and more feasible to provide population-based information on diabetes care.
The HEDIS data cover people enrolled in managedcare plans of different types (commercial insurance, Medicare, and Medicaid), but do not cover people without health insurance (estimated to be 45 million in the US, accounting for 16% of the whole population) [31] . A published national study sheds new light on the quality of health care (including diabetes care) delivered to adults in the US [47] . Based on reviews of medical records, the study found that adherence to the processes relating to six monthly HbA1c testing, ever-documented total cholesterol test, annual urine protein test, and annual eye examinations, were 24%, 58%, 24%, and 14%, respectively. These results were apparently lower than those reported by managed-health plans, indicating quality of diabetes care is lower in the nation as a whole than in those people with health insurance.
Periodical national health surveys
The Behavioural Risk Factor Surveillance System (BRFSS) in the US and the Canadian Community Health Survey collect data annually and every two years respectively, based on interviews of participants. While reporting population based diabetes care process information on a regular and ongoing basis is a major strength of those surveys, recall biases from respondents and lack of information on outcomes (such as HbA1c control) are the major weaknesses. The US National Health and Nutrition Examination Survey (NHANES) collects data using interviews and laboratory tests, lending its capacity to report HbA1c and lipid control among patients with diabetes. In Australia, the National Health Survey (NHS) provided data for estimating prevalence of self-reported diabetes. However, it does not have diabetes-specific components in the questionnaire that allow further analysis of utilisation of diabetes services. The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) was a oneoff population-based survey, ruling out its ability to monitor diabetes care over time.
Our assessment of quality of data sources included in the review showed that the majority of them (11/13) were of satisfactory or good quality. This should encourage policy makers, administrators, and service providers to continue their efforts and investments in the routine data collection systems for ongoing monitoring and improving diabetes care. The poor quality of the two data sources was largely due to poor representativeness in sampling and low national data coverage, highlighting the areas for improvement in the data collection systems.
Strengths and limitations of the present review
We primarily searched websites of health departments and leading national organisations related to diabetes care in each of the five countries, to identify publicly released reports relevant to diabetes care. With the internet playing a significant role in access to and dissemination of information, the search strategy used was well suited to the aims of the review.
This review is subject to some limitations. Due to the evolving nature of website contents (information is added or removed from time to time), there was possibility that some relevant reports might not be captured by the internet search. We updated the search in 2009/2010 after the initial search in 2006 to minimise this limitation.
Caveats in interpreting OECD diabetes indicators Tensions between diabetes performance indicators and clinical practice guidelines
Diabetes clinical guidelines are intended to set optimal standards of care for individual patients by accounting for age and severity of the disease. Unlike clinical guidelines, performance indicators focus on measuring quality of care at a population level and creating a basis for accountability and quality improvement in the health care system [48] . In patients with a variety of disease states, comparison of care across healthcare systems becomes difficult if important confounders (e.g. patients' age and health status) are not adjusted for. TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol.
For the above-mentioned reasons, performance indicators reflect a level of care which is less than the ideal standard, to facilitate comparison across populations without a need for risk adjustment [48] . For example, with regard to frequency of HbA1c testing, the American Diabetes Association's guidelines recommend that HbA1c testing be performed at least once every six months for people with stable blood glucose levels and every three months in those whose therapy has changed or who are not meeting blood glucose goals [38] ; performance indicators, however, only measure whether HbA1c has been tested at least once in the last 12 months.
While clinical guidelines play an essential role in promoting best quality of care for individuals, performance indicators have been primarily employed in an attempt to reflect quality of care at the population level in a convenient and feasible way. It is important to avoid interpretation of indicators as definitions of the "standard of care".
Blood pressure control and foot examination: forgotten areas
The current proposed OECD indicators do not cover services relating to blood pressure control and foot examinations, as these indicators are perceived as not feasible to collect from administrative data sources.
However, in this review, it was found that the most reliable and comprehensive data for current use were obtained from auditing medical records. It is possible to extract data on blood pressure control and foot examinations through this approach.
Therefore, inclusion of blood pressure control and foot examinations in the spectrum of OECD indicators would provide a holistic profile regarding quality of diabetes care. Exclusion of these indicators may risk underestimating their importance in clinical practice and discourage efforts to collect relevant data.
Treatment for patients with diabetes
It is notable that treatment of diabetes has not been directly monitored by OECD indicators, largely due to complexity in data collection. Treatment is tailored for individuals depending on the patient's disease status, and plays a crucial role in diabetes management. Clinical trials have found that a one percentage point reduction in HbA1c levels would reduce micro-vascular complications by 25% to 30% [49, 50] and a 10 mmHg reduction in blood pressure would decrease macro-and micro-vascular complications and death rates by 32% [51] . Improved control of blood lipids can reduce risk of coronary heart disease by 39% and risk of death by 43% [52] .
RAND's Quality Assessment Tools System offers indicators relating to diabetes treatment [53] , and application of these indicators in a national study in the US has provided insight into adherence to recommended treatment regimens. For people with newly diagnosed diabetes 56% received dietary and exercise counselling. In type 2 diabetes patients, use of oral hypoglycaemic agents for those inadequately controlled on dietary therapy was 38% and use of insulin for those inadequately controlled on oral hypoglycaemics was 39%. Fifty-five percent of diabetics were offered an ACE inhibitor within 3 months of the notation of proteinuria unless contraindicated.
The AusDiab study reported the treatment pattern among Australian adults with type 2 diabetes [37] . While 32% of diabetes patients were on diet regimen only, 58% used oral hypoglycaemic agents and diet only, and another 10% took insulin. Bailie and colleagues reported pharmaceutical interventions for diabetes patients in remote Aboriginal communities in the Northern Territory [54] . During the 3-years study period, 75-79% of Aboriginal patients took oral hypoglycaemic agents, and 4-7% used insulin.
Comparison of diabetes care and health system performance across countries
Allowing for the difference in data collection methods, there was relatively wide variation in performance related to processes of diabetes care across the five countries. For example, annual HbA1c testing rates were 64-65% in New Zealand and Australia; the corresponding rate for the UK was 83%. Relatively better performance in such indicators in the UK general practice may be partly due to payment based on capitation, which requires general practitioners to clearly define a population and take a populationbased approach to clinical care [55] . In contrast, most general practitioners in Australia are paid on a fee-forservice basis, with no clearly defined populations for service delivery.
However, relatively less variation was observed in relation to proximal outcomes such as HbA1c control across the countries. To achieve HbA1c control targets as set by clinical guidelines is much more complicated than to simply test HbA1c levels. Previous studies comparing primary care and health system performance in these five countries have identified common deficiencies in health care systems, including poor care coordination and deficient patient-doctor communication [56, 57] . These can result in duplicate tests, delays in care, failure of doctors to discuss care goals and options with patients and to review medication regimens. Such widespread deficiencies across the five countries are likely to contribute to the suboptimal control of HbA1c among patients.
In a recently published OECD Health at a Glance 2009 report [58] , two diabetes-related indicators [admission rates for acute diabetic complications; diabetes lower extremity amputation rates (denominators were general populations rather than peoples with diabetes as specified in the original indicator set listed in Table 3 )], along with the other 21 indicators, have been used to measure health system performance across OECD countries. Diabetes lower extremity amputation rates were higher in the US (36/100,000 population) than in New Zealand, Canada and the UK (9-12/100,000), as were admission rates for acute diabetic complications (57/100,000 versus 1-32/ 100,000). It appeared that diabetes management might be much poorer at the primary care level in the US which led to substantially higher rates of diabetes-related complications. Our review provided evidence of relatively poor control of HbA1c among patients in the US, a direct measure of diabetes management in primary care. With availability and comparability of data up to standard in the future, inclusion of indicators such as HbA1c testing and control into selected OECD health care quality indicators for reporting would enhance understanding of variation in health system performance across countries and point to ways for improvement.
Implications for practice and policy
Measured by OECD diabetes indicators, considerable gaps were revealed in the five selected countries in relation to both optimal diabetes care and availability/quality of data. Countries can learn from each other to strengthen these areas.
For Australia, one of the priorities is to strengthen routine data collection and reporting systems using diabetes registers in general practice, and to improve the coverage of the diabetes registers.
In line with the national funding plan to implement "Strategies for the prevention and control of diabetes in New Zealand", specific funding has been allocated to Maori and Pacific Island people for their own initiatives, including annual free checks and treatment. This designated financial arrangement increased access to high quality diabetes care for Maori and Pacific peoples as well as availability of information. Further implementation of the programme in New Zealand should increase its reach to indigenous and non-indigenous populations in the country. The national diabetes clinical audit system in the UK proves to be a feasible and efficient information system in monitoring diabetes care.
In the US, the most comprehensive and timely data are reported by the National Committee for Quality Assurance to measure performance of managed care plans through the HEDIS. The US Indian Health Service has a well developed Clinical Reporting System to routinely support diabetes care data for American Indians and Alaska Natives. However, for Canada, performance in most key indicators is currently unknown at the national level. Further development of the Canadian National Diabetes Surveillance System might serve as a vehicle to narrow the current information gap.
There is an urgent need for diabetes care information among indigenous populations in Australia and Canada. The process and proximal indicators provide information to inform efforts for prevention and early detection of diabetes-related complications. However, the evidence in this review is especially deficient in these areas for indigenous populations in Australia and Canada. Based on New Zealand and US experiences, with specific commitment to data collection for indigenous populations through effective policy and legislation, it is possible to obtain parallel information for these populations in relation to key indicators of diabetes care.
Conclusions
Substantial efforts have been made in the five countries to develop routine data collection systems to monitor performance of diabetes management. Available performance data identify considerable gaps in clinical care of diabetes across countries. Policy makers and health service providers across countries can learn from each other to improve data collection and delivery of diabetes care at the population level.
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